Alpha Tau Medical Ltd. (DRTS) Stock Price & Analysis

Alpha Tau Medical Ltd. (DRTS) is trading at USD 12.08, down 0.08% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

DRTS last closed at USD 12.08; today's session has ranged USD 11.82–12.22 on volume of 530,909 shares. Market capitalization is —, with a 52-week range of USD 3.43–15.79 (NCM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

What changed for DRTS since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/DRTS.md

Key facts (DRTS)

Superinvestors (SEC 13F-HR, Q3 2026) (DRTS)

1 of 80 tracked investors hold DRTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

InvestorFirm% of portfolioValueChange
Polen CapitalPolen Capital Management0.04%$3.2MReduced -2.0%

Insider sales (SEC Form 4, open-market, last ~7 months) (DRTS)

8 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

Trade dateInsiderRoleSharesValue% of holdings sold10b5-1 planInsider type
2026-08-21Levy RaphiChief Financial Officer2,871$43K3.1%YesToo little history (no open-market trades in 2023–2025)
2026-08-11Levy RaphiChief Financial Officer17,730$248K16.4%YesToo little history (no open-market trades in 2023–2025)
2026-07-06Levy RaphiChief Financial Officer2,270$32K2.5%YesToo little history (no open-market trades in 2023–2025)
2026-07-02Levy RaphiChief Financial Officer17,873$232K16.5%YesToo little history (no open-market trades in 2023–2025)
2026-07-01Levy RaphiChief Financial Officer2,127$28K2.3%YesToo little history (no open-market trades in 2023–2025)
2026-06-30Levy RaphiChief Financial Officer20,000$240K18.2%YesToo little history (no open-market trades in 2023–2025)
2026-06-25Levy RaphiChief Financial Officer20,000$220K15.4%YesToo little history (no open-market trades in 2023–2025)
2026-06-23Levy RaphiChief Financial Officer17,500$167K11.8%YesToo little history (no open-market trades in 2023–2025)
2026-06-03Levy RaphiChief Financial Officer32,500$352K18%NoToo little history (no open-market trades in 2023–2025)

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Total return (dividends reinvested) (DRTS)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return+228.3%+21.9%
S&P 500 (SPY)+11.9%+66.7%
Per year+228.5%+4.0%
Volatility (annualized)76.2%70.3%
Max drawdown-23.9% (Feb 2026→Mar 2026)-84.8% (Mar 2022→Aug 2024)

Dividends (DRTS)

DRTS paid no cash dividend in the last five years.

Short interest (DRTS)

3,920,240 shares sold short, 6.10% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 3,447,381 shares (+13.7%). Days to cover: 8.6 (short shares ÷ average daily volume).

DRTS earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
—Quarter ended Jun 30, 2026−$0.50−$0.14Miss −257.1%—
—Quarter ended Mar 31, 2026−$0.26−$0.12Miss −116.7%—
—Quarter ended Dec 31, 2025−$0.14−$0.12Miss −16.7%—
—Quarter ended Sep 30, 2025−$0.14−$0.12Miss −16.7%—

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

DRTS recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 20266-KCurrent report (foreign issuer) · period ended Nov 16, 2026
Nov 16, 20266-KCurrent report (foreign issuer) · period ended Nov 16, 2026
Nov 12, 20266-KCurrent report (foreign issuer) · period ended Nov 12, 2026
Oct 29, 20266-KCurrent report (foreign issuer) · period ended Oct 29, 2026
Oct 22, 20266-KCurrent report (foreign issuer) · period ended Oct 22, 2026
Oct 19, 20266-KCurrent report (foreign issuer) · period ended Oct 19, 2026
Aug 31, 20266-KCurrent report (foreign issuer) · period ended Aug 31, 2026
Aug 10, 20266-KCurrent report (foreign issuer) · period ended Jun 30, 2026
Aug 10, 20266-KCurrent report (foreign issuer) · period ended Aug 10, 2026
Jul 21, 20266-KCurrent report (foreign issuer) · period ended Jul 21, 2026

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

DRTS suppliers, customers and competitors (named in its 20-F)

RelationshipCompanySentence in the filing
PartnerHekaBio“in our core markets, including the United States and Europe, except for our agreement with HekaBio KK with respect to the commercialization”
PartnerMIM Software“and patent applications related to our Alpha DaRT technology and, other than our collaboration agreement with MIM Software Inc. ("MIM")”
PartnerAlthera Medical“In addition, under the intellectual property purchase agreement with Althera, we assumed all of Althera's liabilities towards the”
PartnerOramed“For example on April 24, 2025, we entered into the Oramed Purchase Agreement with Oramed for the sale by us of 14,110,121 Shares, in a”

Quoted from the company's 20-F filed Mar 9, 2026.

Companies that name DRTS in their SEC reports

Relationship to DRTSCompanyFilingSentence
partnerORAMED PHARMACEUTICALS INC. (ORMP)10-K Mar 26, 2026“subsidiary, Oramed Ltd entered into a share purchase agreement with Alpha Tau Medical Ltd. (Nasdaq: DRTS), or Alpha Tau, a clinical-stage”

DRTS analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Sep 2026)$-0.15$-0.14−$0.01$166,6704
Next quarter (ends Dec 2026)$-0.16$-0.15−$0.01$333,3304
Current fiscal year (ends Dec 2026)$-0.96$-0.88−$0.09$500,0005
Next fiscal year (ends Dec 2027)$-0.54$-0.53−$0.01$10.7M5

DRTS options: expected move

Options price a move of about ±7.7% (±$0.93) by Nov 20, 2026, which includes earnings on Nov 19, 2026.

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262106.7%±7.7%
Dec 18, 20263076.4%±18.2%
Jan 15, 20275872.3%±23.6%
Feb 19, 20279364.7%±26.5%
May 21, 202718466.8%±38.0%

30-day implied volatility 69.5% vs 59.6% realized over the last 30 trading days. Put/call ratio (volume) 0.13. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 12.08
Change▼ 0.08% (down)
Previous CloseUSD 12.08
OpenUSD 12.08
Day RangeUSD 11.82 – 12.22
52-Week RangeUSD 3.43 – 15.79
Volume530,909 shares
Market Cap—
ExchangeNCM

Technical Analysis (DRTS)

Nexqual's technical model rates DRTS "SELL" based on 1 bullish and 5 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalSELL
RSI (14)36.4 (neutral)
vs SMA50Below (USD 13.9)
MACD-0.33 (negative)

Earnings (DRTS)

Next Earnings Date2026-11-19
EPS EstimateUSD -0.15
Revenue Estimate$166,670

Recent Earnings History

QuarterActual vs Estimate
2026-06-30USD -0.5 vs est -0.14 ▼ miss
2026-03-31USD -0.26 vs est -0.12 ▼ miss
2025-12-31USD -0.14 vs est -0.12 ▼ miss
2025-09-30USD -0.14 vs est -0.12 ▼ miss

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (DRTS)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-141.68%
Debt / Equity0.34
Current Ratio11.09
Total Cash$100.64M
Total Debt$15.15M

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (DRTS)

Nexqual rates Alpha Tau Medical Ltd.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetStrong — $101M cash vs $15M debt, net cash position
Cash FlowWeak — Operating cash flow -$13M (TTM)
EfficiencyCritical — ROE -142%, ROA -25.7%

Ownership (DRTS)

Insider Ownership+30.50%
Institutional Ownership+12.01%
Shares Outstanding92.48M
Float64.10M
Short % of Float+6.10%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%
IMVTImmunovant, Inc.USD 33.3▲ 0.27%
AXSMAxsome Therapeutics, Inc.USD 133.9▼ 1.51%
IBRXImmunityBio, Inc.USD 6.71▲ 7.19%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt